

SUPPLEMENT

1. Supplementary Methods

- 1.1. Neuropathological assessment of NFT burden
- 1.2. MEG data preprocessing
- 1.3. Source space reconstruction of MEG sensor data and calculation of neuronal synchrony
- 1.4. Neuropsychological bedside tests

2. Supplementary Figures

- 2.1. Supplementary Figure 1: Frequency-specific neuronal synchrony within select ROI
- 2.2. Supplementary Figure 2: Associations of frequency-specific neuronal synchrony abnormalities and clinical deficits
- 2.3. Supplementary Figure 3: Prediction of NFT density by frequency-specific neuronal synchrony deficits in neocortical ROIs

3. Supplementary Tables

- 3.1. Supplementary Table 1: Demographic and neuropathological characteristics of patients with AD
- 3.2. Supplementary Table 2: Biomarkers of patients with AD at the time of MEG evaluation
- 3.3. Supplementary Table 3: Neuropsychological test performance in patients with AD at the time of MEG evaluation
- 3.4. Supplementary Table 4: Demographic characteristics of control participants
- 3.5. Supplementary Table 5: Anatomical regions selected from Brainnetome atlas parcellations to match the histopathologically defined regions

1. Supplementary Methods

1.1. Neuropathological assessment of NFT burden

The neuroanatomical sampling design and procedures for microscopy using thioflavin-S fluorescent dye used in this study were informed by techniques developed originally by Terry and colleagues.[1] Briefly, 8 μ m-thick paraffin-embedded sections were stained using thioflavin-S, and regions of interest were imaged. Three 0.25 mm² areas (500 μ m x 500 μ m) were sampled at random from each region and quantitative neurofibrillary tangle (NFT) counts were averaged across these three areas to produce a density score. Densities are reported as the number of NFTs per mm². Thioflavin-S identifies tau NFT pathology as well as β -amyloid neuritic plaques.[2] NFT pathology was distinguished from β -amyloid pathology based on the distinct morphological differences between the aggregates. NFT pathology was distinguished by flame-shaped or globose morphology of fibrous neuronal aggregates.

1.2. MEG Data preprocessing

Spectral analysis of each recording was visually inspected and those showing known electrophysiological features of sleep were excluded. Artifact detection was confirmed by visual inspection of sensor data, and channels with excessive noise within individual subjects were removed prior to analysis. The sensor time series were segmented into epochs of 12 s duration. An automatic artifact rejection tool implemented in the Fieldtrip toolbox was used to identify and remove muscle artifacts. An Independent Component Analysis (ICA) based criteria were employed to identify and remove the artifacts created by occasional blinks and cardiac pacing. In addition, noisy epochs caused by minor head and body motions were removed after visual inspection. The remaining cleaned epochs were then filtered using a 1-55 Hz band-pass filter and a maximum of 10 epochs of cleaned-sensor-time-series data were chosen for analysis (i.e. a maximum total of 120 s time-series data per subject).

The signal pre-processing and co-registration were performed by utilizing the Fieldtrip toolbox. To provide anatomical head models for MEG analysis, a high-resolution T1-weighted whole-brain MRI scan was acquired for each subject using the 3 Tesla Siemens Magnetic Resonance Imaging (MRI) scanner at the Neuroscience Imaging Center (NIC) at UCSF. For each subject, the outline of the brain on the structural scans was extracted, and the segmented brain was treated as a volume conductor model for

the source reconstruction described below. MEG sensor data was co-registered to each subject's structural MRI using three fiducial coils placed on the nasion and the left and right preauricular points. For source reconstruction, 6 mm regular voxels were generated in the brain region of a template MRI in MNI space and warped into each individual head model. The magnetic lead field vectors as a forward model were calculated using single-shell-model approximation.

1.3. Source space reconstruction of MEG sensor data and calculation of neuronal synchrony

Source space reconstruction was performed on preprocessed data, using custom-built MATLAB software tools. We applied an array-gain scalar beamforming method to the sensor time series to obtain the source localized activity for all brain regions.[3] The beamformer weights were calculated in the time domain. The data covariance matrix was computed by using the time series data and singular value truncation with 220 components when inverting the matrix. This beamforming provided voxel-level source time courses on 6 mm volumetric grid on brain. We generated the source times courses for the 246 anatomic regions as defined in the Brainnetome atlas, by choosing the time courses of voxels with maximum power within each region.[4]

We computed the average imaginary coherence per ROI, for each subject in our patient group and age-matched controls, within the alpha (8-12 Hz) and delta-theta bands (2-8 Hz). Imaginary coherence captures only the coherence that cannot be explained by volume spread,[5] and is a reliable metric for resting state functional connectivity analyses.[6, 7] For computing the imaginary coherence, we first derived the coherence for each band by dividing the cross-spectrum by auto-spectrum, which were obtained by applying short-time FFT (1.7s Hanning window) to the broad-band 1-55 Hz source time series, and then summing up the Fourier components corresponding to alpha and delta-theta bands. We computed the imaginary coherence per ROI, by averaging across the Fisher's z-transformed values of imaginary part of the coherence. Next, for each patient, we computed z-score estimates of regional alpha and delta-theta imaginary coherence, based on the age-matched control group. For each of the six ROIs, we identified the best representative anatomic region from the Brainnetome atlas in both hemispheres (Supplementary Table 5), and computed the average normalized imaginary coherence (z-score) estimate per subject.

1.4. Neuropsychological bedside tests

Executive function: Set shifting or mental flexibility was assessed by modified Trail Making test.[8] The modified Trail Making test requires the patient to draw lines linking items marked on paper and serially alternate between numbers and days of the week for a period of 120 seconds. The number of correct connections and time taken for the task were recorded. To adjust for the fact that some patients do not complete the task within the required time window of 120 seconds, the dependent measure was calculated as the number of correct connections made per second. Cognitive control was assessed by the Stroop tests [9, 10]. Lexical fluency, was assessed with 'D-words', in which patients generate as many words as possible that are not proper nouns within 60 seconds beginning with the letter 'D'[11, 12]. A nonverbal counterpart of fluency comprises design fluency [8], in which patients are required to use 4 lines to connect the dots within boxes each containing five dots, creating a unique pattern each time. We recorded the number of D-words and patterns patients generated, within 60 seconds. Phonological short-term memory was assessed by digit span forward, and verbal working memory was assessed by digit span backward.

Memory: Verbal episodic memory was evaluated with the California Verbal Learning Test–Short Form (CVLT), which includes a list of 9-item words, presented over 4 learning trials [13]. Immediate (30 seconds) and delayed (10 minutes) CVLT were assessed by free recall of the list at 30-seconds and 10-minutes intervals respectively. The correct number of items recalled, out of 9 were recorded. Visual memory was assessed by asking the patients to draw the Benson figure from memory after a 10-minute delay, and scored on a 17-point scale[14].

Language: Confrontation naming was assessed with a 15-item short form of the Boston Naming Test [15, 16]. The number of correctly named items was recorded out of a total score of 15. Repetition was assessed by having participants repeat 5 phonemically complex sentences. Verbal agility was evaluated by having participants rapidly articulate a multi-syllabic word and was measured as the number of repetitions completed correctly within 5 seconds. Category fluency, was assessed with the ability to generate a list of items within a given category, in which patients generated as many as possible names of animals within 60 seconds [11, 12]. Surface dyslexia was tested by having subjects read 6 irregular words and measured as the number correct out of 6. Syntax comprehension was measured using a subset of 5 items from the


Boston Diagnostic Aphasia Evaluation for which the examiner read a sentence aloud, and the participant had to select from among 4 options the picture that best matched the sentence.

Visuospatial: Subjects were asked to copy a complex figure (Benson figure) as the object of visual construction and the accuracy was scored on a 17-point scale[14]. The Number Location subtest of the Visual Object Space Perception (VOSP)[17] test required the participant to precisely locate a stimulus on a two-dimensional plane, requiring dorsal-stream (“where”) visual processing and scored out of 10. The face matching subtest of the Comprehensive Affect Testing System (CATS)[18] is a ventral-stream task involving 12 trials where the participant determined whether two faces are the same or different.

Emotion naming: The affect matching subtest of the CATS[18] contained 16 trials where the participant was shown a photo of an emotional face and required to select the correct label from a list (i.e. ‘happy’, ‘sad’, ‘angry’, ‘frightened’, ‘surprised’, ‘disgusted’ or ‘neutral’).


2. Supplementary Figures

Supplementary Figure 1




Frequency-specific neuronal synchrony within select ROI: Regional values of imaginary coherence within alpha (A) and delta-theta (B), frequency oscillations in patients with AD and age-matched controls for six regions of interest (ROI) including, angular gyrus (AG), primary motor cortex (PMC), superior temporal gyrus (STG), middle frontal gyrus (MFG), hippocampus-CA1 (CA1), and subiculum (SUBI), in patients with AD. Neuronal synchrony is depicted as the average imaginary coherence estimate per each region (n=13, patients with AD; n=23 age-matched controls). Abbreviations: AD, Alzheimer's disease.

Supplementary Figure 2



Associations of frequency-specific neuronal synchrony abnormalities and clinical deficits: Alpha synchrony deficits showed a significant negative correlation with CDRSOB values (A) while delta-theta synchrony deficits did not show significant correlations with CDRSOB (B) recorded at the time of MEG scan in patients with AD. Each scatter plot depicts the Pearson correlation coefficient and regression lines after correlating the sum of z-scores across the six ROIs within each frequency band and CDRSOB. Abbreviations: CDRSOB, Clinical Dementia Rating Sum-of-Boxes; MEG, magnetoencephalography.

Supplementary Figure 3



Prediction of NFT burden by frequency-specific neuronal synchrony deficits in neocortical ROIs:

Estimates from linear mixed-effects models predicting the NFT burden by alpha (8-12) synchrony deficits (A) and delta-theta (2-8 Hz) synchrony deficits (B), based on the four neocortical regions. Each mixed-effects model included a repeated measured design to include four regions per subject and additional variables of CDR at death, CDRSOB difference from MEG to death and time duration from MEG to death. The model fits depicted in A and B were computed at group averages for other additional variables. (2.45, 9.07, and 4.74, for CDR, CDRSOB difference and time difference, respectively). Raw data points depicting the regional (neocortical only) values of mean NFT densities and mean imaginary coherence in alpha (8-12 Hz) band (C), and delta-theta (2-8 Hz) band (D), in patients with AD. Abbreviations: AG, angular gyrus; AD, Alzheimer's disease; CDR, clinical dementia rating; CDRSOB, clinical dementia rating sum-of-boxes; MEG, magnetoencephalography; MFG, middle frontal gyrus; NFT, neurofibrillary tangle; PMC, primary motor cortex; STG, superior temporal gyrus.

3. Supplementary Tables

3.1. Supplementary Table 1: Demographic and neuropathological characteristics of AD patients

| Case | Sex | Age at disease onset (years) | Age at death (years) | ApoE allele | Clinical syndrome | Brain weight | Braak stage | Thal stage | CERAD score | ABC score |
|------|-----|------------------------------|----------------------|-------------|------------------------|--------------|-------------|------------|-------------|------------|
| 1 | F | 54 | 68 | E3/E3 | PCA | 868 | 6 | 5 | Freq | A3, B3, C3 |
| 2 | M | 58 | 72 | E3/E4 | Amnestic /dysexecutive | 1093 | 6 | 5 | Freq | A3, B3, C3 |
| 3 | M | 58 | 69 | E3/E3 | PCA | 1101 | 6 | 5 | Freq | A3, B3, C3 |
| 4 | M | 47 | 58 | E3/E3 | lvPPA | 1231 | 6 | 5 | Freq | A3, B3, C3 |
| 5 | F | 59 | 67 | E3/E4 | Amnestic /dysexecutive | 1000 | 6 | 5 | Freq | A3, B3, C3 |
| 6 | M | 47 | 59 | E3/E3 | Amnestic /dysexecutive | 1090 | 6 | 5 | Freq | A3, B3, C3 |
| 7 | F | 54 | 64 | E3/E4 | Amnestic /dysexecutive | 870 | 6 | 5 | Freq | A3, B3, C3 |
| 8 | F | 51 | 62 | E3/E4 | PCA | 1005 | 6 | 5 | Freq | A3, B3, C3 |
| 9 | F | 56 | 67 | E4/E4 | Amnestic /dysexecutive | 1001 | 6 | 5 | Freq | A3, B3, C3 |
| 10 | F | 56 | 64 | E3/E3 | Amnestic /dysexecutive | 1061 | 6 | 5 | Freq | A3, B3, C3 |
| 11 | M | 63 | 71 | E3/E4 | Amnestic /dysexecutive | 1199 | 6 | 5 | Freq | A3, B3, C3 |
| 12 | M | 79 | 85 | E3/E3 | Amnestic | 1032 | 5 | 4 | Freq | A3, B3, C3 |
| 13 | F | 56 | 67 | E2/E4 | lvPPA | 970 | 6 | 5 | Freq | A3, B3, C3 |

Abbreviations: ABC score, ABC score for Alzheimer's disease neuropathology; Amnestic/dysexecutive, AD patients with predominant amnestic and dysexecutive symptoms; lvPPA, logopenic variant of primary progressive aphasia; PCA, posterior cortical atrophy syndrome.

3.2. Supplementary Table 2: Biomarkers of AD patients at the time of MEG evaluation

| Case number | CSF | Amyloid [§] | FDG [¶] | MRI |
|-------------|---|----------------------|------------------|--|
| 1 | - | Positive | Positive | Bilateral parietal atrophy with posterior predominance |
| 2 | - | Positive | Positive | Diffuse cortical atrophy with L > R parietal atrophy |
| 3 | A β 42=143 [¥] t-Tau=71 [¥] p-Tau=18 [¥] | Positive | Positive | Hippocampal atrophy and diffuse cortical atrophy predominantly in the L > R occipital and parietal lobes |
| 4 | - | Positive | Positive | L > R parietal atrophy |
| 5 | - | Positive | Positive | L > R hippocampal and parietal atrophy, diffuse white matter changes consistent with cerebral amyloid angiopathy |
| 6 | - | Positive | Positive | Generalized atrophy, predominantly in L > R hippocampal and parietal regions |
| 7 | - | - | - | R > L hippocampal atrophy and diffuse cortical atrophy predominantly in the bilateral dorsal parietal regions |
| 8 | - | Positive | Positive | L > R hippocampal, occipital, and parietal atrophy |
| 9 | - | Positive | Positive | L > R hippocampal atrophy and diffuse cerebral atrophy with posterior predominance |
| 10 | - | Positive | Positive | Bilateral parietal atrophy |
| 11 | - | Positive | Positive | Diffuse atrophy predominantly in the hippocampi and posterior cortex |
| 12 | - | - | - | Bilateral hippocampal atrophy and diffuse cortical atrophy with posterior predominance |
| 13 | - | Positive | Positive | Bilateral parietal atrophy |

Abbreviations: A β 42 = amyloid- β peptide ending in amino acid residue 42; CSF = cerebrospinal fluid; L = left; MRI = magnetic resonance imaging; p-Tau = tau phosphorylated at threonine 181; R = right; t-Tau = total tau.

[§] Positron emission tomography agent was ¹¹C-Pittsburgh compound B.

[¶] Positron emission tomography imaging with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) showing patterns of hypometabolism consistent with Alzheimer's disease.

[¥] Values supporting a diagnosis of Alzheimer's disease are A β 42 level <192 pg/ml, t-Tau level >93 pg/ml, and p-Tau level >23 pg/ml (Alzheimer's Disease Neuroimaging Initiative Biomarker Core at the University of Pennsylvania).

3.3. Supplementary Table 3: Neuropsychological test performance in patients with AD at the time of MEG evaluation

| Variable | Score (Mean ± STD) | z-score (range: min – max) |
|---|-------------------------------|---------------------------------------|
| <u>Episodic memory function</u> | | |
| Visual free recall (Benson 10 minutes) | 3.42 ± 3.48 | -4.11 – -0.58 |
| Short delay verbal memory (CVLT 30 seconds) | 4.31 ± 2.59 | -7.76 – 0.99 |
| Verbal free recall (CVLT 10 minutes) | 2.77 ± 3.44 | -5.51 – 0.78 |
| <u>Executive function & working memory</u> | | |
| Design Fluency | 5.08 ± 3.03 | -3.85 – 0.15 |
| Cognitive control (Stroop Inhibition/color naming) | 0.38 ± 0.25 | -4.91 – 1.33 |
| Verbal working memory (Digit span forward) | 4.46 ± 1.05 | -3.58 – -0.04 |
| Attention (Digit span backward) | 3.00 ± 0.58 | -2.71 – -1.18 |
| Set shifting (Modified trails – speed) | 0.15 ± 0.2 | -2.25 – -0.04 |
| Verbal learning (CVLT total score) | 16.69 ± 5.84 | |
| <u>Language function</u> | | |
| Reading irregular words | 5.25 ± 1.06 | -9.8 – 0.2 |
| Syntax comprehension | 3.15 ± 1.46 | -2.82 – 0.17 |
| Verbal Agility | 3.62 ± 1.45 | -9.75 – 0.52 |
| Boston Naming Test | 11.92 ± 2.53 | -9.19 – 0.70 |
| Lexical Fluency (D words/1 minute) | 9.00 ± 4.43 | -3.96 – -0.10 |
| Category Fluency (Animals/1 minute) | 10.38 ± 4.70 | -3.28 – -0.80 |
| Repetition | 3.00 ± 1.41 | -6.57 – 0.57 |
| <u>Visuospatial function</u> | | |
| Face discrimination (CATS – face matching) | 10.64 ± 1.29 | -5.47 – 0.41 |
| Visuoconstruction (Benson copy) | 9.08 ± 5.63 | -26.46 – 0.46 |
| Location discrimination (VOSP number location) | 6.73 ± 2.53 | -5.08 – 0.81 |
| <u>Calculations</u> | | |
| <i>Emotion naming</i> (CATS – affect matching) | 2.62 ± 0.87 | -6.27 – -1.27 |
| | 11.91 ± 1.45 | -2.78 – 0.36 |

Z-scores were calculated based on age-matched normal control data sets from UCSF-MAC; Abbreviations: CVLT=California Verbal Learning Test; CATS=Comprehensive Affect Testing System; VOSP=Visual Object and Space Perception.

3.4. Supplementary Table 4: Demographic characteristics of controls

| Measure | Control Estimate | Statistical comparison with patients with AD |
|-----------------------------|------------------|--|
| Age at MEG – yr (mean ± SD) | 64.88 ± 5.21 | $t = -0.94, P = 0.351$ |
| Sex (Female) – no. (%) | 14 (60.87%) | $\chi^2 = 0.168, P = 0.68$ |
| Race (White) – no. (%) | 22 (95.65%) | (Fisher's exact test), $P = 1.000$ |
| Handedness (Right) – no.(%) | 18 (78.26%) | (Fisher's exact test), $P = 1.000$ |
| Education – yr (mean ± SD) | 17.60 ± 1.75 | $t = -1.98, P = 0.056$ |
| CDRSOB at MEG (mean ± SD) | 0 ± 0 | $P < 0.0001$ |
| CDR at MEG (mean ± SD) | 0 ± 0 | $P < 0.0001$ |

Abbreviations: AD, Alzheimer's disease; CDR, Clinical Dementia Rating, CDRSOB, CDR Sum-of-Boxes; MEG, Magnetoencephalography

3.5. Supplementary Table 5: Anatomical regions selected from Brainnetome atlas parcellations to match the histopathologically defined regions

| Histopathological regional label | Brainnetome atlas region |
|----------------------------------|--------------------------|
| Middle frontal gyrus (MFG) | A8vl |
| Superior temporal gyrus (STG) | A22c |
| Primary motor cortex (PMC) | A4ul |
| Angular gyrus (AG) | A39rv |
| Hippocampus: CA1 | Caudal hippocampus |
| Hippocampus: Subiculum | Rostral hippocampus |

REFERENCES

- [1] Terry RD, Hansen LA, DeTeresa R, Davies P, Tobias H, Katzman R. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. *J Neuropathol Exp Neurol.* 1987;46:262-8.
- [2] Lamy C, Duyckaerts C, Delaere P, Payan C, Fermanian J, Poulain V, et al. Comparison of seven staining methods for senile plaques and neurofibrillary tangles in a prospective series of 15 elderly patients. *Neuropathol Appl Neurobiol.* 1989;15:563-78.
- [3] Sekihara K, Nagarajan SS, Poeppel D, Marantz A. Asymptotic SNR of scalar and vector minimum-variance beamformers for neuromagnetic source reconstruction. *IEEE transactions on bio-medical engineering.* 2004;51:1726-34.
- [4] Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The Human Brainnetome Atlas: A New Brain Atlas Based on Connectional Architecture. *Cereb Cortex.* 2016;26:3508-26.
- [5] Nolte G, Bai O, Wheaton L, Mari Z, Vorbach S, Hallett M. Identifying true brain interaction from EEG data using the imaginary part of coherency. *Clin Neurophysiol.* 2004;115:2292-307.
- [6] Guggisberg AG, Honma SM, Findlay AM, Dalal SS, Kirsch HE, Berger MS, et al. Mapping functional connectivity in patients with brain lesions. *Ann Neurol.* 2008;63:193-203.
- [7] Hinkley LB, Vinogradov S, Guggisberg AG, Fisher M, Findlay AM, Nagarajan SS. Clinical symptoms and alpha band resting-state functional connectivity imaging in patients with schizophrenia: implications for novel approaches to treatment. *Biol Psychiatry.* 2011;70:1134-42.
- [8] Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan Executive Function System: an update. *J Int Neuropsychol Soc.* 2004;10:301-3.
- [9] Golden CJ. *Stroop Color and Word Test: A manual for clinical and experimental uses.* Chicago, IL: Stoelting Co; 1978.

- [10] Golden CJ. Stroop Color and Word Test: Revised examiner's manual. Wood Dale, IL: Stoelting Co; 2002.
- [11] Benton AL, Hamsher Kd, Sivan AB. Multilingual Aphasia Examination : Third Edition. San Antonio, TX: The Psychological Corporation; 1994.
- [12] Spreen O, Benton AL. Neurosensory Center Comprehensive Examination for Aphasia. Victoria, BC: Neuropsychology Laboratory, University of Victoria; 1977.
- [13] Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test - Second Edition, Adult Version. San Antonio, TX: The Psychological Corporation; 2000.
- [14] Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. *Neuropsychologia*. 2011;49:43-8.
- [15] Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test : Second Edition. Philadelphia: Lippincott Williams and Wilkins; 2001.
- [16] Mack WJ, Freed DM, Williams BW, Henderson VW. Boston Naming Test: shortened versions for use in Alzheimer's disease. *J Gerontol*. 1992;47:P154-8.
- [17] Warrington EK, James M. The Visual Object and Space Perception Battery. Bury St. Edmunds, Suffolk, England: Thames Valley Test Company; 1991.
- [18] Froming K, Levy M, Schaffer S, Ekman P. The comprehensive affect testing system: psychology software, Inc; 2006.